885066-67-1

Basic information

• Product Name: PGD2-inhibitor
• Synonyms: PGD2-inhibitor;PGD2-IN-1
• CAS NO: 885066-67-1
• Molecular Formula: C₂₃H₂₃Cl₂N₃O₃
• Molecular Weight: 460.35302
• EINECS: -0
• Mol File: 885066-67-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 682.1±65.0 °C(Predicted)
• Appearance: /
• Density: 1.326±0.06 g/cm3(Predicted)
• PKA: 4.09±0.10(Predicted)
• CAS DataBase Reference: PGD2-inhibitor(CAS DataBase Reference)
• NIST Chemistry Reference: PGD2-inhibitor(885066-67-1)
• EPA Substance Registry System: PGD2-inhibitor(885066-67-1)

Safety Data

• Hazardous Substances Data: 885066-67-1(Hazardous Substances Data)

Usage

Description

PGD2-inhibitor is a class of chemicals that blocks the action of prostaglandin D2 (PGD2), a lipid molecule involved in physiological processes such as inflammation and allergic reactions. By inhibiting PGD2 production or activity, these chemicals can be used to treat conditions like asthma, allergic rhinitis, and other inflammatory diseases.
Used in Pharmaceutical Industry:
PGD2-inhibitor is used as a therapeutic agent for treating inflammatory conditions such as asthma and allergic rhinitis. It works by reducing the symptoms associated with these conditions by blocking the activity of PGD2, a lipid molecule that plays a role in inflammation and allergic reactions.
Used in Drug Development:
PGD2-inhibitor is used as a target for developing new therapeutic drugs to treat inflammatory diseases. Research has shown that blocking PGD2 activity can lead to a reduction in symptoms, making PGD2-inhibitors a promising avenue for creating effective treatments.

Upstream product

• 885068-00-8 2-(3-boronophenyl)-2-methylpropanoic acid 
• 1016644-41-9 (6-chloro-2-methoxy-pyrimidin-4-yl)-[2-(2,4-dichloro-phenyl)-ethyl]-amine 
• 1098269-51-2 C₁₅H₁₅ClN₂O₃ 
• 52516-13-9 2-(2,4-dichloro-phenyl)-ethylamine 
• 81606-47-5 2-(3-bromophenyl)-2-methylpropanoic acid 
• 1074-40-4 4,6-dichloro-2-methoxypyrimidine 

Downstream Products

• 934815-71-1 2-(3-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxypyrimidin-4-yl)phenyl)-2-methylpropionic acid, phosphate salt 

Relevant articles and documents

A NEW PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL}-PHENYL)- 2-METHYLPROPIONIC ACID

This invention is directed to a process for preparing 2-(3- {6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid.

DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).